Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Henderson, V. W.
Right arrow Articles by Wooten, G. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Henderson, V. W.
Right arrow Articles by Wooten, G. F.
NEUROLOGY 1981;31:132
© 1981 American Academy of Neurology

Neuroleptic malignant syndrome

A pathogenetic role for dopamine receptor blockade?

Victor W. Henderson, M.D. and G. Frederick Wooten, M.D.

From the Department of Neurology, Washington University School of Medicine, St. Louis, MO.

The neuroleptic malignant syndrome (NMS) of extrapyramidal signs and hyperthermia is an uncommon complication of therapy with the major tranquilizers. Other manifestations are pallor, diaphoresis, blood pressure fluctuation, tachycardia, and tachypneic hypoventilation, which may necessitate respirator support. Death often occurs, but full recovery can result with prompt recognition and proper management. In a patient with Parkinson disease and a chronic psychiatric disorder treated with haloperidol, typical features of NMS appeared upon cessation of dopaminergic antiparkinsonian drugs. Manifestations of NMS are attributed to dopamine receptor blockade in the striatum, increasing thermogenesis, and in the hypothalamus, impairing heat dissipation.

Address correspondence and reprint requests to Dr. Henderson, Aphasia/Neurobehavioral Unit, Veterans Administration Hospital, 150 South Huntington Avenue, Boston, MA 02130.

Dr. Wooten is supported by a George C. Cotzias Fellowship from the American Parkinson's Disease Association.

Accepted for publication May 5, 1980




This article has been cited by other articles:


Home page
 CMAJHome page
G. J. Chandran, J. R. Mikler, and D. L. Keegan
Neuroleptic malignant syndrome: case report and discussion
Can. Med. Assoc. J., September 2, 2003; 169(5): 439 - 442.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
M Ueda, M Hamamoto, H Nagayama, S Okubo, S Amemiya, and Y Katayama
Biochemical alterations during medication withdrawal in Parkinson's disease with and without neuroleptic malignant-like syndrome
J. Neurol. Neurosurg. Psychiatry, July 1, 2001; 71(1): 111 - 113.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
P. Adnet, P. Lestavel, and R. Krivosic-Horber
Neuroleptic malignant syndrome
Br. J. Anaesth., July 1, 2000; 85(1): 129 - 135.
[Full Text] [PDF]

Home page
 NeurologyHome page
M. Ueda, M. Hamamoto, H. Nagayama, K. Otsubo, C. Nito, T. Miyazaki, A. Terashi, and Y. Katayama
Susceptibility to neuroleptic malignant syndrome in Parkinson's disease
Neurology, March 1, 1999; 52(4): 777 - 777.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
R. J. Gurrera
Sympathoadrenal Hyperactivity and the Etiology of Neuroleptic Malignant Syndrome
Am J Psychiatry, February 1, 1999; 156(2): 169 - 180.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1981 by AAN Enterprises, Inc.